Systematic Approach to Optimization and Comparability of Biopharmaceutical Glycosylation Throughout the Drug Life Cycle

Biopharmaceutical Production Technology, Volume 1 & Volume 2

Volumn 2, Issue , 2012, Pages 545-583

  Fernandes, Daryl L ^a  

^a Culham Science Centre   (United Kingdom)

Author keywords

Biopharmaceutical; Comparability; Critical quality attribute; Glycosylation; Modeling; Quality by design

Indexed keywords

EID: 84884653540     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527653096.ch17     Document Type: Chapter

References (31)

1. Fernandes, D.L. (2011) Comparability of biopharmaceutical glycosylation during scale-up. Biopharm. Int., Jan, 45-53.
2. International Conference on Harminization (1999) ICH Q6B: Specifi cations: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products. EMA Document CPMP/ICH/365/96. ICH, Geneva.
3. International Conference on Harminization (2003) ICH Q5E: Comparability of Biotechnological/ Biological Products Subject to Changes in their Manufacturing Process. EMA Document CPMP/ICH/5721/03. ICH, Geneva.
4. European Medicines Agency (2009) ICH Q8(R2): Pharmaceutical Development. EMA Document CHMP/ICH/167068/04. EMEA, London.
5. European Medicines Agency (2010) ICH Q8/Q9/Q10: Implementation. EMA Document EMA/CHMP/ICH/265145/2009. EMEA, London.
6. Rathore, A.S. (2009) Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol., 27, 546-553.
7. European Medicines Agency (2007) EMEA Guideline on Development, Production, Characterisation and Specifi cations for Monoclonal Antibodies and Related Products. EMEA/CHMP/ BWP/157653/2007. EMEA, London.
8. Büttel, I.C., Chamberlain, P., Chowers, Y., Ehmann, F., Greinacher, A., Jefferis, R., Kramer, D., Kropshofer, H., Lloyd, P., Lubiniecki, A., Krause, R., Mire-Sluis, A., Platts-Mills, T., Ragheb, J.A., Reipert, B.M., Schellekens, H., Seitz, R., Stas, P., Subramanyam, M., Thorpe, R., Trouvin, J.H., Weise, M., Windisch, J., and Schneider, C.K. (2011) Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals, 39, 100-109.
9. Winkle, H.N. (2007) Implementing quality by design. PDA/FDA Joint Regulatory Conference-Evolution of the Global Regulatory Environment: A Practical Approach to Change, Washington, DC.
10. McVie-Wylie, A.J., Lee, K.L., Qiu, H., Jin, X., Do, H., Gotschall, R., Thurberg, B.L., Rogers, C., Raben, N., O'Callaghan, M., Canfield, W., Andrews, L., McPherson, J.M., and Mattaliano, R.J. (2008) Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab., 94, 448-455.
11. Zhu, Y., Jiang, J.L., Gumlaw, N.K., Zhang, J., Bercury, S.D., Ziegler, R.J., Lee, K., Kudo, M., Canfield, W.M., Edmunds, T., Jiang, C., Mattaliano, R.J., and Cheng, S.H. (2009) Glycoengineered acid alpha-glucosidase with improved effi cacy at correcting the metabolic aberrations and motor function defi cits in a mouse model of Pompe disease. Mol. Ther., 17, 954-963.
12. Mire-Sluis, A., Schenerman, M., Mhatre, R., Advant, S., Dougherty, J., Kozlowski, S., Nashbeh, W., and McLeod, L.D. (2009) Quality by design; the next phase-potential regulatory implications and fi ling of QbD data. BioProcess Int., 2009, 34-42.
13. http://www.casss.org/associations/9165/files/A-MAb_Case_Study_Version_2-1.pdf
14. Bannerjee, A. (2011) Implementing QbD: a process scientist's perspective. Bioprocess International Conference, Nice.
15. Taticek, R. (2010) Quality by Design and its practical application. Seminar in Quality by Design short course, San Diego, April 2010, organized by Cambridge Healthtech Institute.
16. Berridge, J. (2010) John Berridge: How to handle A-Mab, and aspirational and inspirational document. Pharma QbD Expert Insights. http://www.pharmaqbd.com/johnberridge_amab/
17. Hermentin, P., Witzel, R., Kanzy, E.J., Diderrich, G., Hoffmann, D., Metzner, H., Vorlop, J., and Haupt, H. (1996) The hypothetical N-glycan charge: a number that characterizes protein glycosylation. Glycobiology, 6, 217-230.
18. Peipp, M., Lammerts van Bueren, J.J., Schneider-Merck, T., Bleeker, W.W.K., Dechant, M., Beyer, T., Repp, R., van Berkel, P.H.C., Vink, T., van de Winkel, J.G.J., Parren, P.W.H.I., and Valerius, T. (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood, 112, 2390-2399.
19. van Berkel, P.H., Gerritsen, J., Perdok, G., Valbjørn, J., Vink, T., van de Winkel, J.G., and Parren, P.W. (2009) N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol. Prog., 25, 244-251.
20. Houde, D., Peng, Y., Berkowitz, S.A., and Engen, J.R. (2010) Post-translational modifi cations differentially affect IgG1 conformation and receptor binding. Mol. Cell Proteomics, 9, 1716-1728.
21. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., Murphy, B.A., Satinover, S.M., Hosen, J., Mauro, D., Slebos, R.J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D.J., and Platts-Mills, T.A. (2008) Cetuximab-induced anaphylaxis and IgE specifi c for galactose-alpha-1, 3-galactose. N. Engl. J. Med., 358, 1109-1117.
22. van Bueren, J.J.L., Rispens, T., Verploegen, S., van der Palen-Merkus, T., Stapel, S., Workman, L.J., James, H., van Berkel, P.H.C., van de Winkel, J.G.J., Platts-Mills, T.A.E., and Parren, P.W.H.I. (2011) Anti-galactose-a-1, 3-galactose IgE from allergic patients does not bind a-galactosylated glycans on intact therapeutic antibody Fc domains. Nat. Biotechnol., 29, 574-576.
23. Morris, T. (2012) New compendia procedures for characterization of different classes of biopharmaceutical. Biotherapeutics Analytical Summit, March 2012, Baltimore, MD.
24. Domann, P.J., Pardos-Pardos, A.C., Fernandes, D.L., Spencer, D.I., Radcliffe, C.M., Royle, L., Dwek, R.A., and Rudd, P.M. (2007) Separation-based glycoprofi ling approaches using fluorescent labels. Proteomics, 7 (Suppl. 1), 70-76.
25. Fernandes, D.L. (2008) A QbD approach to biopharmaceutical glycosylation, in Quality for Biologics-Critical Quality Attributes, Process and Change Control, Product Variation, Characterisation, and Regulatory Concerns (ed. N. Lyscom), Biopharm Knowledge, Old Basing.
26. Fernandes, D.L. and Spencer, D.I. (2008) Glycoprotein analysis, in Glycoscience-Chemistry and Chemical Biology (eds B.O. Fraser-Reid, K. Tatsuta, and J. Thiem), Springer, Berlin.
27. European Medicines Agency (2005) ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. EMA Documents CPMP/ICH/381/95. EMEA, London.
28. Butler, M. (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol., 68, 283-291.
29. Butler, M. (2010) Characterization and control of protein glycosylation in cell bioprocesses. CHI Post-Translational Modifi cations Conference, San Diego, CA.
30. Legmann, R., Schreyer, H.B., Combs, R.G., McCormick, E.L., Russo, A.P., and Rodgers, S.T. (2009) A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol. Bioeng., 104, 1107-1120.
31. Hossler, P., Khattak, S.F., and Li, Z.J. (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology, 19, 936-949.